News | December 25, 2023
Lyndra Therapeutics raises US$101 million in Series E funding
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired
Development services for gene and cell therapies is planned to begin first in 2025
KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with CTE
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Laurus Synthesis receives Form 483 with 5 observations from USFDA
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Subscribe To Our Newsletter & Stay Updated
